Associated tags: Patient, Steroid, Autoimmunity, Medication, Tissue, Biotechnology, Health, Pharmaceutical, Pharmaceutical industry, Research, Clinical Trials, Endocrinology, Rheumatology, Science, Disease, Polymyalgia rheumatica, Prednisolone, Brain, Liver, Glucocorticoid
Locations: EUROPE, GEORGIA, GERMANY, ROMANIA, BULGARIA, OREGON, UNITED STATES, NORTH AMERICA, CHICAGO, IL
Retrieved on:
Tuesday, October 24, 2023
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Documentation,
United Kingdom,
MRI,
DSM-IV codes,
Medication,
Hyperlipidemia,
NCT,
Mortality,
Endocrinology,
Diabetes,
Disease,
Osteopenia,
Hyperglycemia,
Adrenal tumor,
Hypertension,
ACS,
CT,
Syndrome,
Safety,
Patient,
Death,
Cardiovascular disease,
Rheumatology,
Pharmaceutical industry,
Sparrow This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.
Key Points:
- This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.
- The study will examine SPI-62's effect on morbidities of hypercortisolism including diabetes or impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia.
- Sparrow is actively enrolling up to 30 participants in ACSpire at sites in the United States, soon to be joined by sites in Romania, France, and the United Kingdom.
- To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .
Retrieved on:
Tuesday, September 12, 2023
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Tissue,
Prednisolone,
Endocrinology,
Polymyalgia rheumatica,
PMR,
NCT,
Glucocorticoid,
Toxicity,
Cell,
Medication,
Rheumatology,
Disease,
Steroid,
Liver,
Skin,
Pharmaceutical industry Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, has expanded its PROST!
Key Points:
- Sparrow Pharmaceuticals , an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both rheumatology and endocrinology, has expanded its PROST!
- Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
- For the rheumatology program, a fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.
- To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .
Retrieved on:
Wednesday, August 16, 2023
Research,
FDA,
Clinical Trials,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Male,
Endocrinology,
Criterion,
Syndrome,
Adrenocorticotropic hormone,
Doctor of Philosophy,
Medication,
MD,
Patient,
Rheumatology,
Diagnosis,
ACTH,
Safety,
OLE,
Female,
Pharmaceutical industry The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.
Key Points:
- The long-term OLE will be open to patients who complete the initial RESCUE cross-over treatment protocol and then elect to continue to participate in the research.
- “Cushing’s syndrome can be life-threatening and the preferred first-line surgical treatment often fails.
- While medical therapies are increasingly used, there are many drawbacks and innovative medical approaches have lagged,” said Frank Czerwiec, MD, PhD, Chief Medical Officer of Sparrow.
- Sparrow is actively enrolling the RESCUE trial at approximately 16 sites in the U.S., Bulgaria, and Romania.
Health,
Other Health,
General Health,
Research,
Science,
Pharmaceutical,
Biotechnology,
ENDO,
Prednisolone,
Endocrinology,
FRCP,
University,
Polymyalgia rheumatica,
Sparrow,
University of Leeds,
Cortisol,
Saint Andrew's Society,
Brain,
Doctor of Philosophy,
Medication,
MD,
Rheumatology,
Endocrine Society,
Disease,
Conference,
Pharmaceutical industry,
Fellow of the Academy of Medical Sciences Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference .
Key Points:
- Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference .
- The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.
- Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
- To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com .
Biotechnology,
Pharmaceutical,
Health,
Clinical Trials,
Prednisolone,
Endocrinology,
Depression,
Polymyalgia rheumatica,
Diabetes,
Osteoporosis,
Brain,
Cell,
Weight gain,
Medication,
Hypertension,
Congress,
Adrenal insufficiency,
European,
Risk,
Rheumatology,
European Society of Endocrinology,
Disease,
ECE,
Adrenal crisis,
Pharmaceutical industry Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented an ePoster on its lead candidate and HSD-1 inhibitor SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).
Key Points:
- Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented an ePoster on its lead candidate and HSD-1 inhibitor SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology (ECE 2023).
- “We highlight that, unlike current treatments for Cushing’s syndrome, HSD-1 inhibitors such as SPI-62 might not be expected to carry risk of adrenal crisis,” said Frank Czerwiec, M.D., Ph.D, Chief Medical Officer at Sparrow Pharmaceuticals and ePoster presenter.
- Even with complete HSD-1 inhibition, though, circulating cortisol can diffuse into cells in amounts sufficient to maintain life-critical functions such as stress response.
- To learn more about Sparrow Pharmaceuticals SPI-62, visit www.sparrowpharma.com .
Biotechnology,
Pharmaceutical,
Health,
Clinical Trials,
Prednisolone,
Rheumatology,
Skin,
Patient,
Metabolism,
Toxicity,
HSD,
PMR,
C-reactive protein,
Tissue,
NCT,
Glucocorticoid,
Osteocalcin,
Endocrinology,
Polymyalgia rheumatica,
Knowledge,
Doctor of Philosophy,
Disease,
Liver,
Medication,
Pharmaceutical industry “This trial is expected to teach us whether SPI-62 can separate the desired and undesired effects of prednisolone,” said David Katz, PhD, Chief Scientific Officer of Sparrow.
Key Points:
- “This trial is expected to teach us whether SPI-62 can separate the desired and undesired effects of prednisolone,” said David Katz, PhD, Chief Scientific Officer of Sparrow.
- Patients with PMR taking a daily 10mg oral dose of prednisolone may be eligible for the trial.
- For the PMR trial a fixed-dose combination of prednisolone and SPI-62 will be referred to as SPI-47.
- To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .
Retrieved on:
Sunday, November 13, 2022
Health,
General Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Mouse,
American College of Rheumatology,
Endocrinology,
Atrophoderma,
Disease,
Animal,
Steroid,
Medication,
ACR,
Rheumatology,
Autoimmune disease,
Cardiovascular disease,
Skin,
CORT,
Pharmacology,
Prednisone,
Diabetes,
CSO,
Tissue,
Autoimmunity,
Liver,
Polymyalgia rheumatica,
American College,
Patient,
Prednisolone,
Insulin resistance,
Glucocorticoid,
Brain,
Pharmaceutical industry Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting.
Key Points:
- Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology (ACR) Convergence 2022 meeting.
- The effects of long-term use can be severe, including diabetes, cardiovascular disease, and muscle and skin atrophy.
- An effective glucocorticoid with fewer side effects would be a breakthrough for them, said David A. Katz, Ph.D., CSO at Sparrow Pharmaceuticals.
- The study data presented at ACR demonstrate that SPI-62 can prevent cardiometabolic, muscular, and dermal adverse side effects of CORT in mouse.
Retrieved on:
Wednesday, September 28, 2022
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Adenoma,
Autoimmunity,
Rheumatology,
Safety,
CRH,
Steroid,
Brain,
MD,
Glaucoma,
European Medicines Agency,
Depression,
Hypertension,
ACTH,
Diabetes,
Endocrinology,
Patient,
Osteopenia,
Liver disease,
Disease,
Pain,
Bone loss,
Dyslipidemia,
Female,
Male,
Medication,
Liver,
Doctor of Philosophy,
Adrenocorticotropic hormone,
Tissue,
Diagnosis,
Glucocorticoid,
Sleep,
Muscle,
Tissue (biology),
SME,
Mortality,
Adipose tissue,
EMA,
Hyperglycemia,
Pharmaceutical industry,
EU,
Sparrow This study is one of three phase 2 trials planned to investigate SPI-62 as a treatment for disorders of glucocorticoid excess.
Key Points:
- This study is one of three phase 2 trials planned to investigate SPI-62 as a treatment for disorders of glucocorticoid excess.
- Dosing our first patient in this phase 2 trial is an important milestone in our clinical development process of SPI-62, said Frank Czerwiec, MD, PhD, Chief Medical Officer of Sparrow.
- Cushings is a devastating rare disease with debilitating morbidities such as depression, bone loss, and diabetes, and if left untreated, high levels of mortality.
- The primary endpoint is to determine the pharmacologic effects of SPI-62 in patients with adrenocorticotropic hormone (ACTH)-dependent Cushings syndrome.
Retrieved on:
Friday, September 9, 2022
Health,
Other Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Cardiovascular disease,
Osteocalcin,
Insulin resistance,
Osteoporosis,
Patient,
PMR,
Polymyalgia rheumatica,
Steroid,
Dyslipidemia,
Autoimmune disease,
Vasculitis,
Autoimmunity,
Doctor of Philosophy,
Toxicity,
Rheumatology,
Disease,
Giant cell arteritis,
Medication,
C-reactive protein,
Tissue,
Pains,
NCT,
Glaucoma,
Bruise,
Endocrinology,
Glucocorticoid,
Skin,
ACHES,
Weight gain,
Tissue (biology),
Cortisone,
Stroke,
Hypertension,
Aortic aneurysm,
Bone loss,
GCA,
Myalgia,
Risk,
Motion,
Diabetes,
Insomnia,
Muscle atrophy,
Life,
Degenerative disease,
Prednisolone,
Pharmaceutical industry,
Dietary supplement This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.
Key Points:
- This trial will be the first to evaluate steroid efficacy and toxicity in patients with an autoimmune disease in the presence of a HSD-1 inhibitor.
- If we observe separation of the desired from undesired effects of prednisolone, well be an important step closer to solving a decades-old puzzle in autoimmune disease treatment.
- Patients with PMR taking a daily 10mg oral dose of prednisolone may be eligible for the trial.
- To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Clinical Trials,
ENDO,
Cortisol,
Steroid,
Potent,
Liver,
Medication,
UFC,
ACTH,
Â,
Autoimmunity,
Endocrine system,
Brain,
Cortisone,
Endocrinology,
Patient,
Disease,
Rheumatology,
CSO,
Prednisolone,
Tissue,
Polymyalgia rheumatica,
Pharmaceutical industry,
Medical imaging,
Pig Researchers examined glucocorticoid changes in healthy adults after administration of Sparrows lead therapeutic candidate, SPI-62, a HSD-1 inhibitor.
Key Points:
- Researchers examined glucocorticoid changes in healthy adults after administration of Sparrows lead therapeutic candidate, SPI-62, a HSD-1 inhibitor.
- In fact, studies have shown that UFC normalization doesnt correlate with clinical endpoints in patients with Cushings syndrome.
- The study analyzed historical clinical trial data to better characterize how SPI-62 impacts cortisol levels and the bodys homeostatic response to those changes.
- To learn more about Sparrow Pharmaceuticals and its clinical pipeline, visit the website at www.sparrowpharma.com .
